Dupixent data adds to strong nasal polyps package

Sanofi (Euronext: SAN) and its partner Regeneron (Nasdaq: REGN) have added to the data supporting Dupixent (dupilumab) in severe chronic rhinosinusitis with nasal polyps (CRSwNP) patients who failed previous treatment with surgery or systemic corticosteroids, or both.

The Phase III data from the SINUS-24 and SINUS-52 trials showed that Dupixent (dupilumab), when added to the standard of care corticosteroid nasal spray, improved nasal polyp size, nasal congestion severity, chronic sinus disease, sense of smell and co-morbid asthma outcomes.

"Dupixent is the first biologic therapy to demonstrate the potential to produce disease-modifying effects in severe CRSwNP"